330 related articles for article (PubMed ID: 10991662)
1. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease.
Plaitakis A; Shashidharan P
J Neurol; 2000 Apr; 247 Suppl 2():II25-35. PubMed ID: 10991662
[TBL] [Abstract][Full Text] [Related]
2. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia.
Galter D; Buervenich S; Carmine A; Anvret M; Olson L
Neurobiol Dis; 2003 Dec; 14(3):637-47. PubMed ID: 14678778
[TBL] [Abstract][Full Text] [Related]
3. Glutamate and Parkinson's disease.
Blandini F; Porter RH; Greenamyre JT
Mol Neurobiol; 1996 Feb; 12(1):73-94. PubMed ID: 8732541
[TBL] [Abstract][Full Text] [Related]
4. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE
Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980
[TBL] [Abstract][Full Text] [Related]
5. Properties of dopaminergic neurons in organotypic mesencephalic-striatal co-cultures--evidence for a facilitatory effect of dopamine on the glutamatergic input mediated by α-1 adrenergic receptors.
Cucchiaroni ML; Freestone PS; Berretta N; Viscomi MT; Bisicchia E; Okano H; Molinari M; Bernardi G; Lipski J; Mercuri NB; Guatteo E
Eur J Neurosci; 2011 May; 33(9):1622-36. PubMed ID: 21453288
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease.
Kastner A; Hirsch EC; Herrero MT; Javoy-Agid F; Agid Y
J Neurochem; 1993 Sep; 61(3):1024-34. PubMed ID: 8103078
[TBL] [Abstract][Full Text] [Related]
7. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
8. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
Hartmann A; Michel PP; Troadec JD; Mouatt-Prigent A; Faucheux BA; Ruberg M; Agid Y; Hirsch EC
J Neurochem; 2001 Mar; 76(6):1785-93. PubMed ID: 11259496
[TBL] [Abstract][Full Text] [Related]
9. Nerve tissue-specific (GLUD2) and housekeeping (GLUD1) human glutamate dehydrogenases are regulated by distinct allosteric mechanisms: implications for biologic function.
Plaitakis A; Metaxari M; Shashidharan P
J Neurochem; 2000 Nov; 75(5):1862-9. PubMed ID: 11032875
[TBL] [Abstract][Full Text] [Related]
10. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y
J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900
[TBL] [Abstract][Full Text] [Related]
11. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.
Javoy-Agid F; Hirsch EC; Dumas S; Duyckaerts C; Mallet J; Agid Y
Neuroscience; 1990; 38(1):245-53. PubMed ID: 1979431
[TBL] [Abstract][Full Text] [Related]
12. Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson's Disease.
Zhang Y; Tan F; Xu P; Qu S
Neural Plast; 2016; 2016():8941327. PubMed ID: 26981287
[TBL] [Abstract][Full Text] [Related]
13. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
14. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey.
Smith Y; Charara A; Parent A
J Comp Neurol; 1996 Jan; 364(2):231-53. PubMed ID: 8788247
[TBL] [Abstract][Full Text] [Related]
15. siRNA knock down of glutamate dehydrogenase in astrocytes affects glutamate metabolism leading to extensive accumulation of the neuroactive amino acids glutamate and aspartate.
Skytt DM; Klawonn AM; Stridh MH; Pajęcka K; Patruss Y; Quintana-Cabrera R; Bolaños JP; Schousboe A; Waagepetersen HS
Neurochem Int; 2012 Sep; 61(4):490-7. PubMed ID: 22542772
[TBL] [Abstract][Full Text] [Related]
16. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
[TBL] [Abstract][Full Text] [Related]
17. Neuronal vulnerability in Parkinson's disease.
Hirsch EC; Faucheux B; Damier P; Mouatt-Prigent A; Agid Y
J Neural Transm Suppl; 1997; 50():79-88. PubMed ID: 9120427
[TBL] [Abstract][Full Text] [Related]
18. Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death.
Elstner M; Morris CM; Heim K; Bender A; Mehta D; Jaros E; Klopstock T; Meitinger T; Turnbull DM; Prokisch H
Acta Neuropathol; 2011 Jul; 122(1):75-86. PubMed ID: 21541762
[TBL] [Abstract][Full Text] [Related]
19. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
20. Generation of a Novel Mouse Model of Parkinson's Disease via Targeted Knockdown of Glutamate Transporter GLT-1 in the Substantia Nigra.
Zhang Y; Meng X; Jiao Z; Liu Y; Zhang X; Qu S
ACS Chem Neurosci; 2020 Feb; 11(3):406-417. PubMed ID: 31909584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
